[PDF][PDF] Scintigraphic aspect of Rotor's disease with technetium-99m-mebrofenin

G LeBouthillier, J Morais, M Picard… - Journal of Nuclear …, 1992 - Soc Nuclear Med
G LeBouthillier, J Morais, M Picard, D Picard, R Chartrand, G Pomier
Journal of Nuclear Medicine, 1992Soc Nuclear Med
DISCUSSION Galli and colleagues (1) found that scintigraphic studies differed markedly in
Rotor's disease, depending on which IDA-derivative is being used. They showed that with
die thyl-IDA, liver uptake was absent at 60 mm with only the kidneys and the urinary tract
being visualized. Conversely, when parabutyl-IDA was injected, a faint activity was observed
in the liver with unimpaired excretion, but the kidneys and urinary tract were not seen. In
clinical studies (4),@ mTc@ mebrofeninshowed lower renal excretion and no significant …
DISCUSSION
Galli and colleagues (1) found that scintigraphic studies differed markedly in Rotor's disease, depending on which IDA-derivative is being used. They showed that with die thyl-IDA, liver uptake was absent at 60 mm with only the kidneys and the urinary tract being visualized. Conversely, when parabutyl-IDA was injected, a faint activity was observed in the liver with unimpaired excretion, but the kidneys and urinary tract were not seen. In clinical studies (4),@ mTc@ mebrofeninshowed lower renal excretion and no significant difference in hepatic extraction efficiency, time of maximum hepatic radioac tivity and hepatic parenchymal washout compared to@ thus increasing its availability for hepatic extraction. Our case of Rotor's disease has been studied with 99mTc@ mebrofenin, which showed a slow liver uptake and an unimpaired excretion with the kidneys and urinary tract being visualized throughout the 6-hr imaging interval.
Society of Nuclear Medicine and Molecular Imaging